8-K: STAAR Surgical Reports Q3 2025 Results Amid Alcon Merger

STAAR Surgical Company announced its third quarter 2025 financial results, reporting increased net sales and gross margin, alongside details of its pending acquisition by Alcon Inc.

Summary

• Net sales for the third quarter of 2025 were $94.7 million, representing a 6.9% increase year-over-year.
• Net sales included $25.9 million related to the previously disclosed December 2024 China ICL shipment, which was paid in full during Q3 2025.
• Excluding China, net sales were $38.9 million, an increase of 7.7% year-over-year.
• Gross margin improved to 82.2% in Q3 2025, up from 77.3% in the prior year quarter, primarily due to the timing of cost recognition for the December China Shipment and decreased period costs from Q1 2025 cost reductions.
• Net income for Q3 2025 was $8.9 million, or $0.18 per diluted share, down from $10.0 million, or $0.20 per diluted share, in the prior year quarter.
• Adjusted EBITDA was $34.6 million, or $0.68 per share, a significant increase from $16.2 million, or $0.33 per share, in the prior year quarter.
• Total operating expenses decreased to $59.4 million from $62.8 million year-over-year, driven by cost optimization efforts, despite including $5.9 million in merger transaction and related costs.
• Cash, cash equivalents, and investments available for sale totaled $192.7 million at September 26, 2025, up from $189.9 million at the end of the second quarter of 2025.
• The company repurchased approximately 115,000 shares of its common stock for $2.0 million during Q3 2025, at an average price of $17.20, under its $30 million share repurchase program.
• As of September 26, 2025, approximately $23.5 million remained available under the current share repurchase authorization.
• Sales for the nine months ended September 26, 2025, were lower than the prior year period as distributors in China reduced their inventory by approximately $80 million to $85 million (inclusive of the $27.5 million December China Shipment).

Sentiment

Score: 6

Explanation: While Q3 2025 saw strong revenue growth and Adjusted EBITDA, largely due to the recognition of a delayed China shipment, net income declined year-over-year. The underlying sales growth outside China is positive, and cost optimization efforts are effective. However, the significant inventory reduction by Chinese distributors negatively impacted year-to-date sales, and merger-related costs are present. The pending acquisition by Alcon overshadows the standalone financial performance.

Positives

• Net sales increased by 6.9% year-over-year to $94.7 million, driven by the recognition of the December China Shipment and growth outside China.
• Net sales excluding China demonstrated robust growth of 7.7% year-over-year, reaching $38.9 million, indicating strong underlying business performance in other regions.
• Gross margin significantly improved to 82.2% from 77.3% in the prior year quarter, benefiting from the timing of cost recognition and successful cost reduction initiatives.
• Adjusted EBITDA more than doubled to $34.6 million ($0.68 per share) from $16.2 million ($0.33 per share) year-over-year, reflecting strong operational leverage.
• Operating expenses decreased by 5.4% year-over-year to $59.4 million, demonstrating effective cost optimization efforts despite merger-related costs.
• Operating income surged by 225.4% to $18.5 million from $5.7 million in the prior year quarter.
• The company maintains a strong liquidity position with $192.7 million in cash, cash equivalents, and investments available for sale, and no outstanding debt.
• Continued execution of the share repurchase program, with $2.0 million in shares repurchased during the quarter, signals commitment to shareholder returns.

Negatives

• Net income decreased to $8.9 million ($0.18 per share) from $10.0 million ($0.20 per share) in the prior year quarter, primarily due to lower other income and higher income taxes.
• Sales for the nine months ended September 26, 2025, were significantly lower than the prior year period due to Chinese distributors reducing their inventory by $80 million to $85 million.
• Income taxes increased substantially to $9.9 million from $3.2 million year-over-year, attributed to the reversal of income tax benefits recorded in the first six months of 2025.
• Merger transaction and related costs of $5.9 million impacted operating expenses during the quarter.
• Gain (loss) on foreign currency transactions shifted from a gain of $5.931 million in the prior year quarter to a loss of $0.843 million in Q3 2025.

Risks

• Ability to continue growth and profitability trajectory.
• Reliance on independent distributors in international markets.
• Slowdown or disruption to the Chinese economy.
• Global economic conditions.
• Disruptions in the supply chain.
• Fluctuations in foreign currency exchange rates.
• International trade disputes (including involving tariffs) and substantial dependence on demand from Asia.
• Changes in effective tax rate or tax laws.
• Any loss of use of the principal manufacturing facility.
• Competition.
• Potential losses due to product liability claims.
• Exposure to environmental liability.
• Data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations.
• Acquisitions of new technologies.
• Climate changes.
• Willingness of surgeons and patients to adopt a new or improved product and procedure.
• Extensive clinical trials and resources devoted to research and development.
• Compliance with government regulations.
• Discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action.
• Laws pertaining to healthcare fraud and abuse.
• Changes in FDA or international regulations related to product approval.
• Product recalls or failures.
• The timing of, and completion of, or failure to complete, the pending acquisition of the Company by Alcon Inc.
• Risks related to disruption of management's attention from the Company's ongoing business operations due to the pending acquisition of the Company by Alcon Inc.
• The effect of the announcement of the acquisition of the Company by Alcon Inc. on the ability to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally.

Future Outlook

The company will not host a conference call to review its third quarter 2025 results due to the pending acquisition by Alcon Inc. The forward-looking statements section highlights ongoing risks related to growth, profitability, reliance on international distributors, global economic conditions, supply chain disruptions, and the completion of the Alcon acquisition.

Management Comments

• The company is the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction.
• STAAR has been dedicated solely to ophthalmic surgery since 1982 and has sold more than 3 million ICLs in over 75 countries.

Industry Context

STAAR Surgical operates as the global leader in phakic IOLs, a specialized segment within the broader ophthalmic surgery and vision correction market. The pending acquisition by Alcon Inc., a global leader in eye care, signifies a consolidation trend and potential strategic shift within the industry, aiming to integrate STAAR's innovative ICL technology into a larger portfolio. The challenges in the China market, with distributors reducing inventory, reflect regional market dynamics and potential inventory management issues that can affect medical device companies with significant international exposure.

Comparison to Industry Standards

• The filing identifies STAAR Surgical as the 'global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction,' but does not provide specific comparable company or project data to assess results against global benchmarks.

Stakeholder Impact

• Shareholders: The pending acquisition by Alcon Inc. will significantly impact shareholders, likely leading to a change in ownership and delisting. The ongoing share repurchase program provides some immediate return.
• Employees: The pending acquisition by Alcon Inc. introduces uncertainty regarding future employment, roles, and organizational structure.
• Customers: The company continues to be the global leader in phakic IOLs, providing vision correction solutions. The China inventory situation might affect product availability or pricing dynamics in that region.
• Suppliers: Supply chain disruptions are noted as a risk, indicating potential impacts on suppliers.
• Creditors: The company has no outstanding debt, indicating a strong financial position from a creditor's perspective.

Next Steps

• Completion of the pending acquisition of STAAR Surgical Company by Alcon Inc.
• Continued execution of the $30 million share repurchase program, with approximately $23.5 million remaining.
• Ongoing management of inventory levels and distributor relationships, particularly in China.
• Monitoring and addressing risks related to global economic conditions, supply chain, and foreign currency fluctuations.

Key Dates

Recommendation

Given the pending acquisition by Alcon Inc., the stock's future performance is largely tied to the terms and completion of that transaction rather than standalone operational results. While the company shows strong underlying growth outside China and effective cost management, the overall year-to-date sales are impacted by China inventory issues, and net income declined. Investors should hold, awaiting the finalization of the acquisition, as significant independent upside or downside based solely on these quarterly results is limited by the impending corporate action.

Keywords

STAAR Surgical, STAA, Q3 2025 Earnings, Financial Results, Implantable Collamer Lenses, EVO ICL, Phakic IOLs, Vision Correction, Alcon Acquisition, Ophthalmic Surgery, Medical Devices, China Sales, Gross Margin, Adjusted EBITDA, Share Repurchase